ISSN 2149-2263 | E-ISSN 2149-2271 Home      
 
Volume : 23 Issue : 6
Current Issue Archive Popular Article Ahead of Print

 
Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation [Anatol J Cardiol]
Anatol J Cardiol. 2020; 23(1): 10-18 | DOI: 10.14744/AnatolJCardiol.2019.30766  

Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation

Anetta Undas, Leszek Drabik
John Paul II Hospital, Krakow, Poland

Non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), who had malignant disease. However, their use in cancer patients increases and real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs in cancer patients with AF and the current expert opinions on this subject have been summarized in this review article.

Keywords: anticoagulation, atrial fibrillation, bleeding, cancer, direct oral anticoagulants


Anetta Undas, Leszek Drabik. Non-vitamin K antagonist oral anticoagulants (NOACs) in cancer patients with atrial fibrillation. Anatol J Cardiol. 2020; 23(1): 10-18

Corresponding Author: Anetta Undas, Poland


TOOLS
Full Text PDF
Print
Download citation
RIS
EndNote
BibTex
Medlars
Procite
Reference Manager
Share with email
Share
Send email to author

Similar articles
PubMed
Google Scholar




 
 
KARE Publishing | Copyright 2019 Turkish Society of Cardiology